Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries.
HCV
hepatitis C
low- and middle-income countries
retreatment
treatment failure
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
11 02 2022
11 02 2022
Historique:
received:
24
12
2020
pubmed:
21
5
2021
medline:
15
3
2022
entrez:
20
5
2021
Statut:
ppublish
Résumé
Access to recommended second-line treatments is limited for patients who fail initial hepatitis C virus (HCV) therapy in low- and middle-income countries. Alternative regimens and associated outcomes are not well understood. Through a pooled analysis of national program data in Egypt, Georgia, and Myanmar, we observed SVR rates >90% for alternative retreatment regimens.
Identifiants
pubmed: 34014252
pii: 6279051
doi: 10.1093/cid/ciab461
pmc: PMC8835629
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-516Subventions
Organisme : United Kingdom Foreign, Commonwealth and Development Office
Organisme : Coalition for Global Hepatitis Elimination
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Hepatol Int. 2018 Jul;12(4):356-367
pubmed: 30030720
Hepatology. 2017 Oct;66(4):1083-1089
pubmed: 28498551
Aliment Pharmacol Ther. 2018 Apr;47(7):1023-1031
pubmed: 29377245
Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1245-1250
pubmed: 30791789
J Viral Hepat. 2020 May;27(5):548-551
pubmed: 31894886
World J Hepatol. 2015 Dec 8;7(28):2792-810
pubmed: 26668691
J Hepatol. 2021 Jul;75(1):251-254
pubmed: 33652031
Clin Mol Hepatol. 2019 Dec;25(4):360-365
pubmed: 31042864
N Engl J Med. 2017 Jun 1;376(22):2134-2146
pubmed: 28564569
Adv Virol. 2020 Jul 24;2020:9075905
pubmed: 32774374